Phaarmasia Peer Comparison

Snapshot Summary

Phaarmasia Ltd. is significantly underperforming compared to its peers in the Pharmaceuticals & Drugs industry, showing zero growth in revenue and profitability metrics. The company has a negative PE ratio and lacks efficiency indicators such as ROE and ROA, making it a concerning investment in the current market landscape.

• Phaarmasia Ltd. has zero revenue growth and negative EPS
• It exhibits no profitability or efficiency metrics compared to peers
• Financial indicators suggest it is a high-risk investment with no returns

• Cipla Ltd.: Strong growth with 13.28% YoY revenue increase and solid ROE of 16.63%
• Dr. Reddy's Laboratories Ltd.: Consistently high profitability metrics and 16.54% YoY revenue growth
• Mankind Pharma Ltd.: Highest revenue growth at 18.12% YoY and strong EPS growth at 48.24%

Stocks	CMP	Market Cap	P/E	ROCE (%)	Debt/Equity
Phaarmasia Ltd.	₹32.50	₹22.19Cr	-13.95	-	-
SUNPHARMA	₹1,563.35	₹3,75,099.26Cr	87.59	17.60%	0.04
DIVISLAB	₹6,091.05	₹1,61,698.50Cr	73.20	16.46%	-
CIPLA	₹1,587.60	₹1,28,217.27Cr	23.73	22.77%	0.01
TORNTPHARM	₹3,581.55	₹1,21,215.77Cr	61.53	24.28%	0.57
DRREDDY	₹1,280.30	₹1,06,835.27Cr	15.50	26.86%	0.07
MANKIND	₹2,518.95	₹1,03,926.59Cr	55.18	28.38%	0.02

Explore

Watchlists

Command Palette

Phaarmasia Peer Comparison

Snapshot Summary